524 related articles for article (PubMed ID: 23335675)
21. Raloxifene and the prevention of breast cancer.
Bevers TB
Expert Opin Pharmacother; 2006 Nov; 7(16):2301-7. PubMed ID: 17059385
[TBL] [Abstract][Full Text] [Related]
22. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N;
Cancer Prev Res (Phila); 2010 Jun; 3(6):696-706. PubMed ID: 20404000
[TBL] [Abstract][Full Text] [Related]
23. Prevention of breast cancer in high-risk women.
Kardinal CG; Veith R
J La State Med Soc; 1999 Apr; 151(4):198-201. PubMed ID: 10234895
[TBL] [Abstract][Full Text] [Related]
24. Breast Cancer Chemoprevention among High-risk Women and those with Ductal Carcinoma In Situ.
Reimers LL; Sivasubramanian PS; Hershman D; Terry MB; Greenlee H; Campbell J; Kalinsky K; Maurer M; Jayasena R; Sandoval R; Alvarez M; Crew KD
Breast J; 2015; 21(4):377-86. PubMed ID: 25879521
[TBL] [Abstract][Full Text] [Related]
25. Use of raloxifene and tamoxifen by breast cancer risk level in a Medicare-eligible cohort.
Pinsky PF; Miller E; Heckman-Stoddard B; Minasian L
Am J Obstet Gynecol; 2018 Jun; 218(6):606.e1-606.e9. PubMed ID: 29630889
[TBL] [Abstract][Full Text] [Related]
26. The MORE trial: multiple outcomes for raloxifene evaluation--breast cancer as a secondary end point: implications for prevention.
Dickler MN; Norton L
Ann N Y Acad Sci; 2001 Dec; 949():134-42. PubMed ID: 11795345
[TBL] [Abstract][Full Text] [Related]
27. The use of tamoxifen and raloxifene for the prevention of breast cancer.
Wickerham DL; Costantino JP; Vogel VG; Cronin WM; Cecchini RS; Ford LG; Wolmark N
Recent Results Cancer Res; 2009; 181():113-9. PubMed ID: 19213563
[TBL] [Abstract][Full Text] [Related]
28. Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).
Runowicz CD; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Ford LG; Vogel VG; Wolmark N
Am J Obstet Gynecol; 2011 Dec; 205(6):535.e1-5. PubMed ID: 21872200
[TBL] [Abstract][Full Text] [Related]
29. Effects of tamoxifen and raloxifene on memory and other cognitive abilities: cognition in the study of tamoxifen and raloxifene.
Legault C; Maki PM; Resnick SM; Coker L; Hogan P; Bevers TB; Shumaker SA
J Clin Oncol; 2009 Nov; 27(31):5144-52. PubMed ID: 19770382
[TBL] [Abstract][Full Text] [Related]
30. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010.
Waters EA; McNeel TS; Stevens WM; Freedman AN
Breast Cancer Res Treat; 2012 Jul; 134(2):875-80. PubMed ID: 22622807
[TBL] [Abstract][Full Text] [Related]
31. Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR).
Cecchini RS; Costantino JP; Cauley JA; Cronin WM; Wickerham DL; Bandos H; Weissfeld JL; Wolmark N
Cancer Prev Res (Phila); 2012 Nov; 5(11):1321-9. PubMed ID: 23060039
[TBL] [Abstract][Full Text] [Related]
32. Breast cancer prevention with selective estrogen receptor modulators: a perspective.
Pritchard KI
Ann N Y Acad Sci; 2001 Dec; 949():89-98. PubMed ID: 11795385
[TBL] [Abstract][Full Text] [Related]
33. Chemoprevention of breast cancer: a summary of the evidence for the U.S. Preventive Services Task Force.
Kinsinger LS; Harris R; Woolf SH; Sox HC; Lohr KN
Ann Intern Med; 2002 Jul; 137(1):59-69. PubMed ID: 12093250
[TBL] [Abstract][Full Text] [Related]
34. Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials.
Cecchini RS; Costantino JP; Cauley JA; Cronin WM; Wickerham DL; Land SR; Weissfeld JL; Wolmark N
Cancer Prev Res (Phila); 2012 Apr; 5(4):583-92. PubMed ID: 22318751
[TBL] [Abstract][Full Text] [Related]
35. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women.
Bevers TB
J Natl Compr Canc Netw; 2007 Sep; 5(8):719-24. PubMed ID: 17927929
[TBL] [Abstract][Full Text] [Related]
36. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
[TBL] [Abstract][Full Text] [Related]
37. Projecting individualized absolute invasive breast cancer risk in African American women.
Gail MH; Costantino JP; Pee D; Bondy M; Newman L; Selvan M; Anderson GL; Malone KE; Marchbanks PA; McCaskill-Stevens W; Norman SA; Simon MS; Spirtas R; Ursin G; Bernstein L
J Natl Cancer Inst; 2007 Dec; 99(23):1782-92. PubMed ID: 18042936
[TBL] [Abstract][Full Text] [Related]
38. The selective estrogen receptor modulators in breast cancer prevention.
Li F; Dou J; Wei L; Li S; Liu J
Cancer Chemother Pharmacol; 2016 May; 77(5):895-903. PubMed ID: 26787504
[TBL] [Abstract][Full Text] [Related]
39. Risk versus Benefit of Chemoprevention among Raloxifene and Tamoxifen Users with a Family History of Breast Cancer.
Anderson C; Nichols HB; House M; Sandler DP
Cancer Prev Res (Phila); 2019 Nov; 12(11):801-808. PubMed ID: 31431499
[TBL] [Abstract][Full Text] [Related]
40. Selective estrogen receptor modulators (SERMs) and retinoids in breast cancer chemoprevention.
Zujewski J
Environ Mol Mutagen; 2002; 39(2-3):264-70. PubMed ID: 11921197
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]